endo.digital Platform— 510(k) K232722

Substantially Equivalent

DreaMed Diabetes, Ltd.

FDA 510(k) clearance K232722 for endo.digital Platform, Substantially Equivalent on 2023-10-03. Applicant: DreaMed Diabetes, Ltd..

Clearance details

Applicant: DreaMed Diabetes, Ltd.
Product code: Code QCC
Advisory panel: Clinical Chemistry
Date received: 2023-09-05
Decision date: 2023-10-03
Decision: Substantially Equivalent
Clearance type: Special
Location: Petah Tikva, IL

Download summary PDF View on FDA.gov ↗

Data sourced from openFDA. This site is unofficial and independent of the FDA.